Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on “Chemokine CXCL13 in serum, CSF, and blood-CSF barrier function”

Pilz et al. (Fluids Barriers CNS 17:7; 2020) investigated how CSF CXCL13 concentrations are influenced by CXCL13 serum concentrations and blood-CSF barrier (BCSFB) perform, evaluating the affect of serum CXCL13 ranges and Qalbumin (CSF albumin/serum albumin) on CSF CXCL13 amongst sufferers with CNS irritation categorized as CXCL13 unfavourable, low, medium, or excessive.
Among all CXCL13 teams, their outcomes confirmed no correlation between CSF CXCL13 concentrations and serum CXCL13 or Qalbumin. The authors argue that, in distinction to different proteins, CXCL13 passage throughout the BCSFB doesn’t happen, no matter BCSFB perform, and is as an alternative solely influenced by intrathecal manufacturing.
In distinction to the authors’ findings, in our research together with each non-inflammatory neurological issues (NIND; n = 62) and a number of sclerosis (MS) sufferers we noticed a big correlation between serum CXCL13 concentrations and CSF CXCL13 concentrations.
We evaluation a number of observations which can underlie these contrasting outcomes, together with (1) the affect of serum CXCL13 concentrations on CSF CXCL13 in sufferers with decrease intrathecal CXCL13 manufacturing and thus decrease CXCL13 concentrations (i.e. NIND and MS), (2) the proposed diffusion dynamics of the small molecule CXCL13 throughout the BCSFB, and (3) differing definitions of unfavourable versus elevated CSF CXCL13 concentrations decided by an assay’s relative sensitivity. In conclusion, we argue that for sufferers with reasonably elevated CSF CXCL13 concentrations, serum CXCL13 concentrations affect CSF CXCL13 ranges, and thus the suitable corrections together with incorporation of CSF/serum ratios and Qalbumin values must be utilized.

The Specific Judo Training Program Combined With the Whole Body Cryostimulation Induced an Increase of Serum Concentrations of Growth Factors and Changes in Amino Acid Profile in Professional Judokas

This research aimed to guage the impact of a selected coaching program, supported by 10 classes of complete physique cryostimulation, on progress elements concentrations, amino acids profile and motor skills in skilled judokas. Ultimately, twelve athletes took half in the research. They had been randomly assigned to the cryostimulation group (CRY, n = 6) or the management group (CON, n = 6). During 2 weeks of the judo coaching program, the CRY group carried out 10 cryo-sessions (3-min, at a temperature of -110°C) and the CON group rested passively.
Anthropometric measurements, a energy take a look at, the Special Judo Efficiency Test (SJET) had been assessed 2 days earlier than and after the judo coaching program. Blood samples had been collected at relaxation, 1 h after the primary and the second SJET and 1 h after the primary and the final cryo-session to ascertain progress elements and amino acid concentrations.
Lactate degree was measured earlier than, instantly after and 1 h after the primary and the second SJET. The utilized intervention resulted in a big improve of resting concentrations of brain-derived neurotrophic issue (from 10.23 ± 1.61 to 15.13 ± 2.93 ng⋅ml-1p = 0.01) and insulin-like progress issue 1 (IGF-1; from 174.29 ± 49.34 to 300.50 ± 43.80 pg⋅ml-1p = 0.00) in the CRY group.
Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on "Chemokine CXCL13 in serum, CSF, and blood-CSF barrier function"
A totally different response was registered 1 h immediately put up SJET in the CRY group (a big improve of IGF-1, interleukin 15 and irisin: p = 0.01; p = 0.00; p = 0.03). Additionally, the numerous drop of proline and leucine concentrations in the CRY group was obtained. Athletes’ efficiency remained unchanged in each teams. However, topics perceived constructive adjustments induced by the intervention – in a roundabout way after cryostimulation however in response to the particular coaching workload. The improve of progress elements concentrations and the advance of amino acid profile (proline and leucine) contributed to sustaining a excessive degree of muscle perform.

Multivariate Investigation of Toxic and Essential Metals in the Serum from Various Types and Stages of Colorectal Cancer Patients

Colorectal most cancers (CRC) is at the moment one of the crucial frequent malignant neoplasms, rating third in incidence and 2nd in mortality each in the USA and internationally. The pathogenesis of CRC is a posh interplay between genetic susceptibility and environmental elements resembling publicity to metals. Therefore, the current research was meant to evaluate the imbalances in the concentrations of chosen important/poisonous parts (Pb, Cr, Fe, Zn, As, Cd, Cu, Se, Ni, and Hg) in the serum of newly identified colorectal carcinoma sufferers (n = 165) in comparability with counterpart controls (n = 151) by atomic absorption spectrometry after wet-acid digestion technique.
Serum carcinoembryonic antigen (CEA) of the CRC sufferers was decided utilizing immunoradiometric technique. Body mass index (BMI) which is a longtime threat issue for CRC was additionally calculated for sufferers and wholesome controls. Conversely, common Ni (2.721 μg/g), Cd (0.563 μg/g), As (0.539 μg/g), and Pb (1.273 μg/g) ranges had been considerably elevated in the serum of CRC sufferers in comparison with the wholesome donors, whereas the typical Se (7.052 μg/g), Fe (15.67 μg/g), Cu (2.033 μg/g), and Zn (8.059 μg/g) concentrations had been elevated in controls.
The correlation coefficients between the weather in the cancerous sufferers demonstrated considerably dissimilar communal relationships in contrast with the wholesome topics. Significant variations in the basic ranges had been additionally confirmed for CRC varieties (major colorectal lymphoma, gastrointestinal stromal tumor, and adenocarcinoma) and CRC levels (stage-I, stage-II, stage-III, and stage-IV) among the many sufferers. Majority of the weather demonstrated perceptible disparities in their ranges based mostly on dietary, habitat, gender, and smoking habits of the malignant sufferers and wholesome topics.

SAA4 Polyclonal Antibody

ES7118-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against SAA4 from Human. This antibody is tested and validated for IHC, WB, ELISA

SAA4 Polyclonal Antibody

ES7118-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against SAA4 from Human. This antibody is tested and validated for IHC, WB, ELISA

Anti-SAA4 antibody

STJ118868 100 µl
EUR 277

SAA4 Polyclonal Antibody

ABP56119-003ml 0.03ml
EUR 158
Description: A polyclonal antibody for detection of SAA4 from Human. This SAA4 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human SAA4 at AA range: 50-130

SAA4 Polyclonal Antibody

ABP56119-01ml 0.1ml
EUR 289
Description: A polyclonal antibody for detection of SAA4 from Human. This SAA4 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human SAA4 at AA range: 50-130

SAA4 Polyclonal Antibody

ABP56119-02ml 0.2ml
EUR 414
Description: A polyclonal antibody for detection of SAA4 from Human. This SAA4 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human SAA4 at AA range: 50-130

Anti-SAA4 antibody

STJ95571 200 µl
EUR 197
Description: Rabbit polyclonal to SAA4.

SAA4 Conjugated Antibody

C43534 100ul
EUR 397

anti- SAA4 antibody

FNab07574 100µg
EUR 585
Description: Antibody raised against SAA4

Anti-SAA4 antibody

PAab07574 100 ug
EUR 412

SAA4 siRNA

20-abx932387
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol

SAA4 siRNA

20-abx932388
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol

anti-SAA4

YF-PA14502 50 ug
EUR 363
Description: Mouse polyclonal to SAA4

anti-SAA4

YF-PA14503 100 ul
EUR 403
Description: Rabbit polyclonal to SAA4

anti-SAA4

YF-PA14504 100 ug
EUR 403
Description: Rabbit polyclonal to SAA4

anti-SAA4

YF-PA24657 50 ul
EUR 334
Description: Mouse polyclonal to SAA4

SAA4 cloning plasmid

CSB-CL020659HU-10ug 10ug
EUR 233
Description: A cloning plasmid for the SAA4 gene.

Human SAA4 Protein

abx060004-100ug 100 ug
EUR 328

SAA4 Rabbit pAb

A16428-100ul 100 ul
EUR 308

SAA4 Rabbit pAb

A16428-200ul 200 ul
EUR 459

SAA4 Rabbit pAb

A16428-20ul 20 ul
EUR 183

SAA4 Rabbit pAb

A16428-50ul 50 ul
EUR 223

SAA4 Blocking Peptide

DF7899-BP 1mg
EUR 195

Anti-SAA4 (3C11)

YF-MA15335 100 ug
EUR 363
Description: Mouse monoclonal to SAA4

SAA4 Blocking Peptide

33R-8261 100 ug
EUR 180
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of SAA4 antibody, catalog no. 70R-5922

SAA4 Blocking Peptide

33R-1030 100 ug
EUR 180
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of PHF20L1 antibody, catalog no. 70R-8973

Monoclonal SAA4 Antibody, Clone: EPR2926

AMR09806G 0.1ml
EUR 528
Description: A Monoclonal antibody against Human SAA4. The antibodies are raised in Rabbit and are from clone EPR2926. This antibody is applicable in WB and IHC

Polyclonal SAA4 Antibody (C-term)

AMR09807G 0.1ml
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human SAA4 (C-term). This antibody is tested and proven to work in the following applications:

Anti-SAA4/Serum Amyloid A4 Antibody

A07115 100ul
EUR 397
Description: Rabbit Polyclonal SAA4/Serum Amyloid A4 Antibody. Validated in IHC and tested in Human.

Serum Amyloid A4, Constitutive (SAA4) Antibody

20-abx128626
  • EUR 425.00
  • EUR 133.00
  • EUR 1205.00
  • EUR 578.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Serum Amyloid A4, Constitutive (SAA4) Antibody

20-abx323184
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug

Serum Amyloid A4, Constitutive (SAA4) Antibody

20-abx174526
  • EUR 857.00
  • EUR 439.00
  • 1 mg
  • 200 ug

Mouse SAA4 shRNA Plasmid

20-abx972561
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg

Human SAA4 shRNA Plasmid

20-abx954237
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg

Human SAA4 ELISA Kit

ELA-E10316h 96 Tests
EUR 824

SAA4 ELISA KIT|Human

EF002194 96 Tests
EUR 689

SAA4 Recombinant Protein (Human)

RP027541 100 ug Ask for price

SAA4 Recombinant Protein (Mouse)

RP169868 100 ug Ask for price

SAA4 Recombinant Protein (Rat)

RP227402 100 ug Ask for price

SAA4 protein (His tag)

80R-1554 50 ug
EUR 397
Description: Purified recombinant Human SAA4 protein

Human Serum Amyloid A-4 (SAA4) Antibody

13031-05011 150 ug
EUR 217

Serum Amyloid A-4 Protein (SAA4) Antibody

abx029249-400ul 400 ul
EUR 523

Serum Amyloid A-4 Protein (SAA4) Antibody

abx029249-80l 80 µl
EUR 286

Serum Amyloid A-4 Protein (SAA4) Antibody

abx237574-100ug 100 ug
EUR 551

Serum amyloid A /SAA4/CSAA

E21-F15 10ug
EUR 343

SAA4 ELISA Kit (Human) (OKEH02075)

OKEH02075 96 Wells
EUR 662
Description: Description of target: ;Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.1 ng/mL

SAA4 ELISA Kit (Human) (OKCD08499)

OKCD08499 96 Wells
EUR 975
Description: Description of target: SAA4 is a major acute phase reactant. It is an Apolipoprotein of the HDL complex.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 0.063ng/mL

SAA4 ELISA Kit (Mouse) (OKEH05734)

OKEH05734 96 Wells
EUR 779
Description: Description of target: Major acute phase reactant. Apolipoprotein of the HDL complex. ;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.082 ng/mL

SAA4 ELISA Kit (Bovine) (OKEH07586)

OKEH07586 96 Wells
EUR 1092
Description: Description of target: ;Species reactivity: Bovine;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity:

Saa4 ORF Vector (Rat) (pORF)

ORF075802 1.0 ug DNA
EUR 506

SAA4 ORF Vector (Human) (pORF)

ORF009181 1.0 ug DNA
EUR 95

Saa4 ORF Vector (Mouse) (pORF)

ORF056624 1.0 ug DNA
EUR 506

SAA2-SAA4 Recombinant Protein (Human)

RP095754 100 ug Ask for price

Recombinant Serum Amyloid A4, Constitutive (SAA4)

4-RPD529Hu01
  • EUR 496.03
  • EUR 236.00
  • EUR 1585.12
  • EUR 595.04
  • EUR 1090.08
  • EUR 395.00
  • EUR 3812.80
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Serum Amyloid A4, Constitutive expressed in: E.coli

Saa4 sgRNA CRISPR Lentivector set (Mouse)

K3373601 3 x 1.0 ug
EUR 339

SAA4 sgRNA CRISPR Lentivector set (Human)

K2084901 3 x 1.0 ug
EUR 339

Saa4 sgRNA CRISPR Lentivector set (Rat)

K7166301 3 x 1.0 ug
EUR 339

SAA2-SAA4 ORF Vector (Human) (pORF)

ORF031919 1.0 ug DNA Ask for price

Serum Amyloid A4, Constitutive (SAA4) Polyclonal Antibody (Human, Mouse)

4-PAD529Hu01
  • EUR 247.00
  • EUR 2510.00
  • EUR 625.00
  • EUR 310.00
  • EUR 214.00
  • 100ul
  • 10ml
  • 1ml
  • 200ul
  • 20ul
Description: A Rabbit polyclonal antibody against Human, Mouse Serum Amyloid A4, Constitutive (SAA4)

Human Serum Amyloid A-4 (SAA4) Antibody (Biotin Conjugate)

13031-05021 150 ug
EUR 276

SAA4 Serum Amyloid A4 Human Recombinant Protein

PROTP35542 Regular: 10ug
EUR 317
Description: SAA4 Human Recombinant fused with a 21 amino acid His tag at N-terminus produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 131 amino acids (21-130 a.a.) and having a molecular mass of 14.9kDa. The SAA4 is purified by proprietary chromatographic techniques.

Human Serum Amyloid A4, Constitutive (SAA4) Protein

20-abx167047
  • EUR 690.00
  • EUR 286.00
  • EUR 2138.00
  • EUR 829.00
  • EUR 495.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Saa4 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K3373602 1.0 ug DNA
EUR 154

Saa4 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K3373603 1.0 ug DNA
EUR 154

Saa4 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K3373604 1.0 ug DNA
EUR 154

SAA2-SAA4 sgRNA CRISPR Lentivector set (Human)

K2800601 3 x 1.0 ug
EUR 339

SAA4 sgRNA CRISPR Lentivector (Human) (Target 1)

K2084902 1.0 ug DNA
EUR 154

SAA4 sgRNA CRISPR Lentivector (Human) (Target 2)

K2084903 1.0 ug DNA
EUR 154

SAA4 sgRNA CRISPR Lentivector (Human) (Target 3)

K2084904 1.0 ug DNA
EUR 154

Saa4 sgRNA CRISPR Lentivector (Rat) (Target 1)

K7166302 1.0 ug DNA
EUR 154

Saa4 sgRNA CRISPR Lentivector (Rat) (Target 2)

K7166303 1.0 ug DNA
EUR 154

Saa4 sgRNA CRISPR Lentivector (Rat) (Target 3)

K7166304 1.0 ug DNA
EUR 154

SAA4 Protein Vector (Rat) (pPB-C-His)

PV303206 500 ng
EUR 603

SAA4 Protein Vector (Rat) (pPB-N-His)

PV303207 500 ng
EUR 603

SAA4 Protein Vector (Rat) (pPM-C-HA)

PV303208 500 ng
EUR 603

SAA4 Protein Vector (Rat) (pPM-C-His)

PV303209 500 ng
EUR 603

SAA4 Protein Vector (Human) (pPB-C-His)

PV036721 500 ng
EUR 329

SAA4 Protein Vector (Human) (pPB-N-His)

PV036722 500 ng
EUR 329

SAA4 Protein Vector (Human) (pPM-C-HA)

PV036723 500 ng
EUR 329

SAA4 Protein Vector (Human) (pPM-C-His)

PV036724 500 ng
EUR 329

Recombinant Human SAA4 Protein, His, E.coli-10ug

QP13410-10ug 10ug
EUR 201

Recombinant Human SAA4 Protein, His, E.coli-1mg

QP13410-1mg 1mg
EUR 5251

Recombinant Human SAA4 Protein, His, E.coli-2ug

QP13410-2ug 2ug
EUR 155

SAA4 Protein Vector (Mouse) (pPB-C-His)

PV226494 500 ng
EUR 603

SAA4 Protein Vector (Mouse) (pPB-N-His)

PV226495 500 ng
EUR 603

SAA4 Protein Vector (Mouse) (pPM-C-HA)

PV226496 500 ng
EUR 603

SAA4 Protein Vector (Mouse) (pPM-C-His)

PV226497 500 ng
EUR 603

SAA4 3'UTR GFP Stable Cell Line

TU072548 1.0 ml
EUR 1394

Saa4 3'UTR Luciferase Stable Cell Line

TU219889 1.0 ml Ask for price

SAA4 3'UTR Luciferase Stable Cell Line

TU022548 1.0 ml
EUR 1394

Saa4 3'UTR GFP Stable Cell Line

TU269889 1.0 ml Ask for price

Saa4 3'UTR Luciferase Stable Cell Line

TU118311 1.0 ml Ask for price
Multivariate strategies revealed noticeably divergent apportionment among the many poisonous/important parts in the cancerous sufferers than the wholesome counterparts. Overall, the research confirmed considerably divergent distribution and associations of the important and poisonous elemental ranges in the serum of the CRC sufferers in comparability with the wholesome donors.

Serum carnitine concentration and the acyl to free carnitine ratio in nondialysis chronic kidney disease and hemodialysis patients

Mechanisms of impaired fatty acid metabolism will not be the similar in nondialysis and hemodialysis patients. Correlations between the serum free carnitine concentration (FC), acylcarnitine concentration (AC), acyl to free carnitine ratio (AC/FC) and estimated glomerular filtration charge (eGFR) in the nondialysis inhabitants and the length of hemodialysis in hemodialysis patients have been investigated. As the eGFR decreased, the FC and AC elevated, and as the length of hemodialysis turned longer, the FC and AC decreased.
The AC/FC elevated constantly as the eGFR decreased and the length of hemodialysis elevated. As an exception, the AC/FC decreased in the patients with a hemodialysis length lower than 90 days, which was not defined by carnitine elimination by hemodialysis. In nondialysis patients, a useful, somewhat than an absolute, carnitine deficiency is a primary reason behind impaired fatty acid metabolism. Long-term hemodialysis exacerbates absolute carnitine deficiency, whereas hemodialysis therapy might enhance impaired fatty acid metabolism.

Effects of Dietary Indole-3-Acetate Sodium on Laying Performance, Egg Quality, Serum Hormone Levels and Biochemical Parameters of Danzhou Chickens

This examine was carried out to examine the results of indole-3-acetate sodium (IAA-Na) inclusion in diets on the egg manufacturing efficiency, egg high quality, intestinal tissue morphology, serum hormone ranges and biochemical parameters of Danzhou chickens to preliminarily discover the efficacy of IAA-Na as a feed additive. A complete of 192 Danzhou chickens (50 weeks previous) have been randomly assigned to 2 teams of 96. The diets for the therapy group consisted of the basal diets, supplemented with IAA-Na (200 mg/kg).
The formal feeding trial lasted for 4 weeks. The outcomes confirmed that the feed supplemented with IAA-Na not solely elevated the laying charge (p < 0.05) and egg yolk ratio (0.05 < p < 0.1), but additionally considerably lowered the feed:egg ratio (p < 0.05). In addition, the dietary supplementation of IAA-Na considerably elevated the serum estradiol ranges (p < 0.05) and decreased serum alkaline phosphatase exercise (p < 0.05).
Compared with the management group, the addition of IAA-Na to the weight-reduction plan had no important impact on the intestinal tissue morphology or serum antioxidant capability of Danzhou chickens. This examine preliminarily gives proof that dietary IAA-Na can enhance laying efficiency, indicating that IAA-Na is a doubtlessly efficient feed additive for laying hens, however additional research are required earlier than arriving at particular conclusions.

The Effects of Zinc Sulfate Supplementation on Serum Copeptin, C-Reactive Protein and Metabolic Markers in Zinc-Deficient Diabetic Patients on Hemodialysis: A Randomized, Double-Blind, Placebo-Controlled Trial

We aimed to examine the affiliation between zinc (Zn) supplementation and serum ranges of copeptin, high-sensitive C-reactive protein (hs-CRP), glycemic management, anthropometric parameters and renal operate in Zn -deficient diabetic hemodialysis patients (DHPs). This randomized, double-blind, placebo-controlled trial (RCT) was carried out on 46 DHPs with Zn-deficiency.
The Zn complement group (n = 21) acquired a 220-mg/day Zn sulfate capsule (containing 50 mg Zn), and the management group (n = 25) acquired a placebo capsule (220 mg corn starch), for eight weeks. Fasting, predialysis blood samples have been taken at baseline and after eight weeks to assess fasting blood glucose (FBG), serum insulin, copeptin, high-sensitive C-reactive protein (hs-CRP), blood urea nitrogen (BUN), creatinine (Cr) concentrations, and homoeostatic mannequin evaluation (HOMA-IR) and quantitative insulin-sensitivity verify index (QUICKI).
Compared to controls, serum copeptin (P < 0.001), hs-CRP (P < 0.001), BUN (P < 0.001), Cr (P < 0.001), Zn (P < 0.001), FBG (P < 0.001) ranges, BMI (P < 0.001), and physique weight (P < 0.001) have been considerably affected following ZnSO4 supplementation for eight weeks. In distinction, QUICKI (P = 0.57), HOMA-IR (P = 0.60), and serum insulin (P = 0.55) weren’t affected following Zn supplementation in comparability with patients receiving placebo. Zn sulfate supplementation seems to have favorable results on serum copeptin and hs-CRP, FBG, and renal operate in Zn-deficient DHPs. Iranian Registry of Clinical Trials Identifier: IRCT20190806044461N1.

Effects of Psychostimulants and Antipsychotics on Serum Lipids in an Animal Model for Schizophrenia

Schizophrenia (SCZ) therapy is basically restricted to the use of typical or atypical antipsychotic medicine, which suppress the primary signs of this psychological dysfunction. Metabolic syndrome is commonly reported in patients with SCZ underneath long-term drug therapy, however little is thought about the alteration of lipid metabolism induced by antipsychotic use. In this examine, we evaluated the blood serum lipids of a validated animal mannequin for SCZ (Spontaneously Hypertensive Rat, SHR), and a traditional management rat pressure (Normotensive Wistar Rat, NWR), after long-term therapy (30 days) with typical haloperidol (HAL) or atypical clozapine (CLZ) antipsychotics.
Serum carnitine concentration and the acyl to free carnitine ratio in nondialysis chronic kidney disease and hemodialysis patients
Moreover, psychostimulants, amphetamine (AMPH) or lisdexamfetamine (LSDX), have been administered to NWR animals aiming to mimic the human first episode of psychosis, and the results on serum lipids have been additionally evaluated. Discrepancies in lipids between SHR and NWR animals, which included elevated complete lipids and decreased phospholipids in SHR in contrast with NWR, have been comparable to the variations beforehand reported for SCZ patients relative to wholesome controls.
Administration of psychostimulants in NWR decreased omega-3, which was additionally decreased in the first episode of psychosis of SCZ. Moreover, choline glycerophospholipids allowed us to distinguish the results of CLZ in SHR. Thus, modifications in the lipid metabolism in SHR appear to be reversed by the long-term therapy with the atypical antipsychotic CLZ, which was underneath the similar situation described to reverse the SCZ-like endophenotypes of this validated animal mannequin for SCZ.

Human Serum Albumin antibody

10C-CR2116M3 1 mg
EUR 176
Description: Mouse monoclonal Human Serum Albumin antibody

Human Serum Albumin antibody

10R-10574 100 ug
EUR 349
Description: Mouse monoclonal Human Serum Albumin antibody

Human Serum Albumin antibody

10R-8417 100 ul
EUR 393
Description: Mouse monoclonal Human Serum Albumin antibody

Human Serum Albumin antibody

10R-A120a 1 mg
EUR 460
Description: Mouse monoclonal Human Serum Albumin antibody

Human Serum Albumin antibody

10R-A120b 1 mg
EUR 460
Description: Mouse monoclonal Human Serum Albumin antibody

Human Serum Albumin antibody

10R-A120c 1 mg
EUR 489
Description: Mouse monoclonal Human Serum Albumin antibody

Human Serum Albumin antibody

10R-A120d 1 mg
EUR 475
Description: Mouse monoclonal Human Serum Albumin antibody

Human Serum Albumin antibody

70R-AG008 1 mg
EUR 300
Description: Goat Purified polyclonal Human Serum Albumin antibody

Human Serum Albumin antibody

70R-AR008 1 mg
EUR 1847
Description: Affinity purified Rabbit polyclonal Human Serum Albumin antibody

Serum Albumin Antibody

48145-100ul 100ul
EUR 333

Serum Albumin Antibody

48145-50ul 50ul
EUR 239

Albumin Human Serum

abx082261-250mg 250 mg
EUR 203

Human Serum Albumin

7-05389 100mg Ask for price

Human Serum Albumin

7-05390 500mg Ask for price

Human Serum Albumin

7-05391 5gram Ask for price

Human Serum Albumin

4016-10MG
EUR 495

Human Serum Albumin

4016-1MG
EUR 180

Human Serum Albumin

30R-2429 10 mg
EUR 597
Description: Purified native Human Serum Albumin

Human Serum Albumin

30R-3302 10 mg
EUR 349
Description: Purified native Human Serum Albumin

Polyclonal Human Serum Albumin Antibody

APR07896G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Human Serum Albumin . This antibody is tested and proven to work in the following applications:

Monoclonal Human Serum Albumin Antibody

APR07897G 0.1ml
EUR 484
Description: A Monoclonal antibody against Human Human Serum Albumin. The antibodies are raised in Mouse. This antibody is applicable in WB

Monoclonal Human Serum Albumin Antibody

APR07898G 0.1ml
EUR 484
Description: A Monoclonal antibody against Human Human Serum Albumin. The antibodies are raised in Mouse. This antibody is applicable in WB

Human Serum Albumin (ALB) Antibody

20-abx134557
  • EUR 356.00
  • EUR 537.00
  • EUR 217.00
  • 100 ul
  • 200 ul
  • 30 ul

Human Serum Albumin (ALB) Antibody

20-abx134558
  • EUR 356.00
  • EUR 537.00
  • EUR 217.00
  • 100 ul
  • 200 ul
  • 30 ul

Human Serum Albumin Antibody (HRP)

20-abx134559
  • EUR 384.00
  • EUR 606.00
  • EUR 230.00
  • 100 ul
  • 200 ul
  • 30 ul

Human Serum Albumin Antibody (FITC)

20-abx134560
  • EUR 384.00
  • EUR 606.00
  • EUR 230.00
  • 100 ul
  • 200 ul
  • 30 ul

Human Serum Albumin (ALB) Antibody

abx019111-100ug 100 ug
EUR 342

Human Serum Albumin Polyclonal Antibody

A57544 100 µg
EUR 570.55
Description: reagents widely cited

Human Serum Albumin Polyclonal Antibody

A57748 100 µg
EUR 570.55
Description: fast delivery possible

Anti-Human Serum Albumin antibody

STJ99077 200 µl
EUR 197
Description: Mouse monoclonal to Human Serum Albumin.

Anti-Human Serum Albumin antibody

STJ99078 200 µl
EUR 197
Description: Mouse monoclonal to Human Serum Albumin.

Human Serum Albumin Conjugated Antibody

C48062 100ul
EUR 397

Human Serum Albumin Monoclonal Antibody

A1022-100
EUR 387

Human Serum Albumin antibody (Glycated)

10-A67A 100 ug
EUR 396
Description: Mouse monoclonal Human Serum Albumin antibody (Glycated)

Human Serum Albumin antibody (FITC)

60R-AG005FT 500 ug
EUR 241
Description: Goat polyclonal Human Serum Albumin antibody (FITC) conjugated

Human Serum Albumin antibody (biotin)

60R-AR006bt 1 mg
EUR 1860
Description: Rabbit polyclonal Human Serum Albumin antibody (biotin) conjugated

Human Serum Albumin antibody (HRP)

60R-AR007hrp 1 mg
EUR 1830
Description: Rabbit polyclonal Human Serum Albumin antibody (HRP) conjugated

Serum Albumin Antibody (FITC)

20-abx106448
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin Antibody (HRP)

20-abx107862
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx109288
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx109420
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110206
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110207
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110528
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110530
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110537
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110584
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110585
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110594
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110618
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110620
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110644
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110645
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110646
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum Albumin (ALB) Antibody

20-abx110647
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Serum albumin (ALB) Antibody

20-abx339064
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul

Serum albumin (ALB) Antibody

20-abx339065
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul

Serum Albumin Antibody (Biotin)

20-abx105033
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Bovine Serum Albumin Antibody

20-abx133923
  • EUR 356.00
  • EUR 537.00
  • EUR 217.00
  • 100 ul
  • 200 ul
  • 30 ul

Bovine Serum Albumin Antibody

20-abx133926
  • EUR 356.00
  • EUR 537.00
  • EUR 217.00
  • 100 ul
  • 200 ul
  • 30 ul

Serum Albumin Antibody (Biotin)

20-abx134561
  • EUR 384.00
  • EUR 606.00
  • EUR 230.00
  • 100 ul
  • 200 ul
  • 30 ul

Bovine Serum Albumin Antibody

20-abx134562
  • EUR 356.00
  • EUR 537.00
  • EUR 217.00
  • 100 ul
  • 200 ul
  • 30 ul

Serum albumin (ALB) Antibody

20-abx211456
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul

Serum Albumin Conjugated Antibody

C48145 100ul
EUR 397

Mouse Serum Albumin antibody

20R-AR005 20 mg
EUR 327
Description: Rabbit polyclonal Mouse Serum Albumin antibody

Rat Serum Albumin antibody

20R-AR023 20 mg
EUR 327
Description: Rabbit polyclonal Rat Serum Albumin antibody

Mouse Serum albumin antibody

20R-AR041 2 ml
EUR 295
Description: Rabbit polyclonal Mouse Serum albumin antibody

Canine Serum Albumin antibody

70R-15096 100 ug
EUR 327
Description: Rabbit polyclonal Canine Serum Albumin antibody

Chicken Serum Albumin antibody

70R-15097 100 ug
EUR 327
Description: Rabbit polyclonal Chicken Serum Albumin antibody

Goat Serum Albumin antibody

70R-15100 100 ug
EUR 327
Description: Rabbit polyclonal Goat Serum Albumin antibody

Horse Serum Albumin antibody

70R-15104 100 ug
EUR 327
Description: Rabbit polyclonal Horse Serum Albumin antibody

Mouse Serum Albumin antibody

70R-AG001 1 mg
EUR 256
Description: Affinity purified Goat polyclonal Mouse Serum Albumin antibody

Recombinant Human Serum Albumin

7-06151 10mg Ask for price

Recombinant Human Serum Albumin

7-06152 50mg Ask for price

Recombinant Human Serum Albumin

7-06153 100mg Ask for price

Recombinant Human Serum Albumin

RP-797 5 mg
EUR 286

OryzaExp? Human Serum Albumin

P1396-1
EUR 436

Human Serum Albumin protein

30-1137 5 gram
EUR 242
Description: native Human Serum Albumin

Human Serum Albumin protein

30-1951 1 g
EUR 220
Description: Lyophilized Human Serum Albumin (>96% pure)

Human Serum Albumin protein

30-AA73 1 gram
EUR 452
Description: Cell culture grade recombinant Human Serum Albumin protein

Bovine Serum Albumin

HY-D0842 10g
EUR 187

Bovine Serum Albumin

GE1877-250G 250 g
EUR 285

Bovine Serum Albumin

GE1877-25G 25 g
EUR 70

Bovine Serum Albumin

GE1877-500G 500 g
EUR 500

Bovine Serum Albumin

GE1877-100G 100 g
EUR 158

Bovine Serum Albumin

GE1877-10G 10 g
EUR 54

Bovine Serum Albumin

GE1877-50G 50 g
EUR 102

Bovine Serum Albumin

7-04585 10gr Ask for price

Bovine Serum Albumin

7-04586 50gr Ask for price

Bovine Serum Albumin

7-04587 100gr Ask for price

Serum Albumin Protein

20-abx263082
  • EUR 230.00
  • EUR 328.00
  • 100 mg
  • 500 mg

Serum Albumin Protein

abx263082-5gr 5 gr
EUR 1066

Rat Serum Albumin

30R-3297 10 mg
EUR 187
Description: Purified native Rat Serum Albumin

Pigeon Serum Albumin

30R-3298 10 mg
EUR 327
Description: Purified native Pigeon Serum Albumin
These knowledge open new insights for understanding the potential affect of the therapy with typical or atypical antipsychotics on circulating lipids. This might signify an consequence impact from metabolic pathways that regulate lipids synthesis and breakdown, which can be reflecting a cell lipids dysfunction in SCZ.

Serum myokine levels after linear and flexible non-linear periodized resistance training in overweight sedentary women

This research in contrast the capability of linear-(LP) and non-linear periodized (NLP) resistance training to enhance choose myokines and metabolic parameters in overweight sedentary women. An further function was to match these variables between the overweight and lean women. Fitness- and age-matched overweight women between 28 and 43 years outdated had been randomly allotted to LP (physique fats [BF]% = 38.7 ± 2.6, n=10), NLP (BF% = 39.3 ± 2.4, n=9) and management (BF% = 39.8 ± 2.6, n=9) teams. Lean women (BF% = 29.1 ± 2.3, n=16) matched for age and health had been additionally included for baseline comparability.
Resistance training applications (12 weeks, Three d.wk-1, 9 workouts, 60 to 90% of 1-repetition most [1RM]) had been carried out with totally different periodization schemes. Glucose, insulin, interleukin (IL)-7, IL-15, and insulin-like development issue (IGF)-1 levels had been measured at baseline and after training. Overweight topics had considerably decrease IL-15, IGF-1 and increased insulin, glucose, and insulin resistance (homeostasis mannequin evaluation, HOMA-IR) than lean topics at baseline (all, P<0.05).
IL-15 and VO2max elevated considerably after NLP in contrast with CON, which was accompanied by a major lower in HOMA-IR (all, P<0.03). Muscular endurance improved considerably in each fashions after training in comparison with CON (all, P<0.01), nevertheless it elevated extra in NLP than in LP (P=0.01). Both training protocols had been equally efficient at lowering BF% and growing IGF-1, IL-7, muscle mass and bench press 1RM (P<0.01). It seems that LP and NLP are each efficient methods for enhancing well being markers in overweight women, however LP isn’t as efficient as NLP to enhance IL-15, HOMA-IR, and cardio capability.

The Effects of Serum Removal on Gene Expression and Morphological Plasticity Markers in Differentiated SH-SY5Y Cells

Despite the widespread use of the SH-SY5Y human neuroblastoma cell line in modeling human neurons in vitro, protocols for development, differentiation and experimentation differ significantly throughout the literature. Many research totally differentiate SH-SY5Y cells earlier than experimentation, to research plasticity measures in a mature, human neuronal-like cell mannequin. Prior to experimentation, serum is usually faraway from cell tradition media, to arrest the cell development cycle and synchronize cells.
However, the precise impact of this serum elimination earlier than experimentation on mature, differentiated SH-SY5Y cells has not but been described. In research utilizing differentiated SH-SY5Y cells, any impact of serum elimination on plasticity markers might affect outcomes. The goal of the present research was to systematically characterize, in differentiated, neuronal-like SH-SY5Y cells, the possibly confounding results of full serum elimination in phrases of morphological and gene expression markers of plasticity.
We measured modifications in generally used morphological markers and in genes associated to neuroplasticity and synaptogenesis, significantly in the BDNF-TrkB signaling pathway. We discovered that full serum elimination from already differentiated SH-SY5Y cells will increase neurite size, neurite branching, and the proportion of cells with a main neurite, in addition to proportion of βIII-Tubulin and MAP2 expressing cells.
Gene expression outcomes additionally point out elevated expression of PSD95 and NTRK2 expression 24 h after serum elimination. We conclude that serum deprivation in differentiated SH-SY5Y cells impacts morphology and gene expression and can probably confound plasticity-related end result measures, having vital implications for experimental design in research utilizing differentiated SH-SY5Y cells as a mannequin of human neurons.

Coronary calcification is related to elevated serum lipoprotein (a) levels in asymptomatic males over the age of 45 years: A cross-sectional research of the Korean nationwide well being checkup information

Lipoprotein a (Lp (a)) and coronary artery calcification (CAC) are markers of coronary artery and cardiovascular illnesses. However, the affiliation between Lp (a) and CAC in asymptomatic people stays unclear. In this research, we aimed to find out the affect of Lp (a) on CAC in asymptomatic people.
We included 2019 asymptomatic Korean adults who underwent testing for a coronary artery calcium rating (CACS) and Lp (a) on the Gangnam Severance Hospital Health Checkup Center in Korea from January 2017 to August 2019. Participants had been divided into 2 teams: CACS = 0 and CACS > 0. Factors affecting the CACS had been analyzed by intercourse. Because age is a serious threat issue for atherosclerosis, ≥45 years in males and ≥55 years in women, we additional divided individuals into Four subgroups (≥45 and <45 in males, ≥55 and <55 in women).
Factors affecting the CACS in the Four teams had been analyzed.There was a constructive correlation between the CACS and conventional cardiovascular threat components. Lp (a) positively correlated with the CACS in males (P < .01) and remained vital after multivariable logistic regression (P < .01). The similar outcome was noticed in males aged ≥45 years (P < .01).Lp (a) is an independently related issue of CAC and a marker of coronary atherosclerosis in asymptomatic males aged ≥45 years. In asymptomatic males aged ≥45 years, Lp (a) ought to be measured, and intensive Lp (a)-lowering remedy ought to be thought-about.

Association of Serum Vitamin D and Immunoglobulin E Levels With Severity of Allergic Rhinitis

Objective The goal of this research was to find out the affiliation of serum vitamin D and immunoglobulin E (IgE) levels with the severity of allergic rhinitis (AR). Methods This case-control research was performed at Mayo Hospital, Lahore, from June to September 2020 after acquiring moral approval. Patients of AR had been included and divided with the assistance of allergic rhinitis and its affect on bronchial asthma (ARIA) classification, into group A (circumstances), sufferers presenting with reasonable to extreme signs, and into group B (management), sufferers with delicate signs, after remedy of AR.
Serum myokine levels after linear and flexible non-linear periodized resistance training in overweight sedentary women
The imply distinction between serum IgE and serum Vitamin D levels of each teams had been in contrast by t-test. Association was decided by logistic regression and odds ratio. Results A complete of 224 sufferers had been included in the research, 112 sufferers in group A and 112 sufferers in group B. There had been 106 (47.3%) feminine and 118 (52.7%) male.
The imply age of sufferers in group A was 26.78± 8.92 years and in group B, it was 25.72±8.12 years. Mean serum vitamin D levels in group A had been 16.24±6.7 ng/ml and in group B 26.92±35 ng/ml (p=0.0001). Mean serum IgE levels in group A had been 383.69±154.86 IU/ml and in group B, they had been 373.03±106.83 IU/ml (p=0.0001).

SAA1 Antibody

10R-11514 1 mg
EUR 261
Description: Anti-Human SAA1 Monoclonal Antibodies

SAA1 Antibody

10R-11515 1 mg
EUR 261
Description: Anti-Human SAA1 Monoclonal Antibodies

SAA1 Antibody

10R-11516 1 mg
EUR 261
Description: Anti-Human SAA1 Monoclonal Antibodies

SAA1 Antibody

10R-11517 1 mg
EUR 261
Description: Anti-Human SAA1 Monoclonal Antibodies

SAA1 protein

30R-2980 10 ug
EUR 241
Description: Purified recombinant Monkey SAA1 protein

Beaucage reagent

HY-100951 10mM/1mL
EUR 126

BOP reagent

5-02141 25g Ask for price

BOP reagent

5-02142 100g Ask for price

Bradford reagent

BDE641 100ml
EUR 61.01

BOP reagent

A7015-100000 100 g
EUR 200
Description: A peptide coupling reagent. Can be used in the preparation of phenyl esters of amino acids which have been shown to be valuable as blocked derivatives of amino acids in the field of peptide synthesis.

BOP reagent

A7015-25000 25 g
EUR 113
Description: A peptide coupling reagent. Can be used in the preparation of phenyl esters of amino acids which have been shown to be valuable as blocked derivatives of amino acids in the field of peptide synthesis.

Bluing Reagent

BRT030 30 ml
EUR 60

Bluing Reagent

BRT125 125 ml
EUR 63

Bluing Reagent

BRT3800 1 Gal.
EUR 184

Bluing Reagent

BRT500 500 ml
EUR 76

Bluing Reagent

BRT999 1000 ml
EUR 88

Traut's Reagent

2330-1000
EUR 349

Traut's Reagent

2330-500
EUR 207

MTS Reagent

2808-1000
EUR 990

MTS Reagent

2808-250
EUR 365

MTT Reagent

2809-1G
EUR 180

MTT Reagent

2809-5G
EUR 544

Chymase reagent

30C-CP1129 5 units
EUR 2185
Description: Purified native Human Chymase reagent

SAA1 cloning plasmid

CSB-CL365776HU-10ug 10ug
EUR 233
Description: A cloning plasmid for the SAA1 gene.

SAA1 Polyclonal Antibody

ES11982-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against SAA1 from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA

SAA1 Polyclonal Antibody

ES11982-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against SAA1 from Human/Mouse. This antibody is tested and validated for WB, ELISA, WB, ELISA

Anti-SAA1 antibody

STJ25438 100 µl
EUR 277
Description: This gene encodes a member of the serum amyloid A family of apolipoproteins. The encoded preproprotein is proteolytically processed to generate the mature protein. This protein is a major acute phase protein that is highly expressed in response to inflammation and tissue injury. This protein also plays an important role in HDL metabolism and cholesterol homeostasis. High levels of this protein are associated with chronic inflammatory diseases including atherosclerosis, rheumatoid arthritis, Alzheimer's disease and Crohn's disease. This protein may also be a potential biomarker for certain tumors. Alternate splicing results in multiple transcript variants that encode the same protein. A pseudogene of this gene is found on chromosome 11.

Anti-SAA1 antibody

STJ116764 100 µl
EUR 277
Description: This gene encodes a member of the serum amyloid A family of apolipoproteins. The encoded preproprotein is proteolytically processed to generate the mature protein. This protein is a major acute phase protein that is highly expressed in response to inflammation and tissue injury. This protein also plays an important role in HDL metabolism and cholesterol homeostasis. High levels of this protein are associated with chronic inflammatory diseases including atherosclerosis, rheumatoid arthritis, Alzheimer's disease and Crohn's disease. This protein may also be a potential biomarker for certain tumors. Alternate splicing results in multiple transcript variants that encode the same protein. A pseudogene of this gene is found on chromosome 11.

Anti-SAA1 antibody

STJ193140 200 µl
EUR 197
Description: Unconjugated Rabbit polyclonal to SAA1

Anti-SAA1 antibody

STJ160130 1 mL C
EUR 1647

Anti-SAA1 antibody

STJ400172 1 mg
EUR 446
Description: Serum amyloid A, a family of apolipoproteins, is associated with high density lipoprotein during inflammatory states. The level of serum amyloid A (SAA) in the blood increases dramatically in response to tissue injury and inflammation. SAA also acts as a cytokine, influencing cell adhesion, migration, proliferation and aggregation. SAAs are implicated in several chronic inflammatory diseases, such as amyloidosis, atherosclerosis, and rheumatoid arthritis.

Anti-SAA1 antibody

STJ400173 1 mg
EUR 446
Description: Serum amyloid A, a family of apolipoproteins, is associated with high density lipoprotein during inflammatory states. The level of serum amyloid A (SAA) in the blood increases dramatically in response to tissue injury and inflammation. SAA also acts as a cytokine, influencing cell adhesion, migration, proliferation and aggregation. SAAs are implicated in several chronic inflammatory diseases, such as amyloidosis, atherosclerosis, and rheumatoid arthritis.

Human SAA1 Protein

abx060040-100ug 100 ug
EUR 328

SAA1 Rabbit pAb

A14553-100ul 100 ul
EUR 308

SAA1 Rabbit pAb

A14553-200ul 200 ul
EUR 459

SAA1 Rabbit pAb

A14553-20ul 20 ul
EUR 183

SAA1 Rabbit pAb

A14553-50ul 50 ul
EUR 223

SAA1 Polyclonal Antibody

ABP60318-003ml 0.03ml
EUR 158
Description: A polyclonal antibody for detection of SAA1 from Human, Mouse. This SAA1 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human SAA1 protein

SAA1 Polyclonal Antibody

ABP60318-01ml 0.1ml
EUR 289